{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T13:58:24Z","timestamp":1774619904794,"version":"3.50.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[1999,10,1]],"date-time":"1999-10-01T00:00:00Z","timestamp":938736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Interleukin-2 (IL-2), a product of activated T-cells, is now being used in a number of protocols for cancer immunotherapy. In one stem cell transplantation protocol for breast cancer, IL-2 is used together with interferon- \u03b3 (IFN- \u03b3 ) and cyclosporine to stimulate a graft-versus-tumor response and improve the likelihood of a prolonged remission. We present the case of a patient who developed peripheral eosinophilia, perihilar infiltrates, and hypoxemia after autologous stem cell transplantation and the use of recombinant IL-2 and IFN- \u03b3. Histologic analysis of transbronchial lung biopsies demonstrated a few eosinophils within the bronchial submucosa. Immunostaining using antibodies directed against eosinophil major basic protein (MBP), however, revealed massive extracellular deposition of this toxic granule protein throughout the lung parenchyma. IL-2 therapy is well known to induce a peripheral eosinophilia and to be associated with the capillary leak syndrome characterized by weight gain, edema, and oliguria. The findings noted in this case report suggest that the eosinophil activation that accompanies immunologic therapy with IL-2 can result in direct toxicity to the lung and a localized vascular leak syndrome. This syndrome should be considered in the differential diagnosis of pulmonary infiltrates that occur acutely after bone marrow transplantation with cytokine augmentation.<\/jats:p>","DOI":"10.1164\/ajrccm.160.4.9902048","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T14:04:20Z","timestamp":1365084260000},"page":"1361-1365","source":"Crossref","is-referenced-by-count":9,"title":["Pulmonary Infiltrates after Cytokine Therapy for Stem Cell Transplantation: Massive Deposition of Eosinophil Major Basic Protein Detected by Immunohistochemistry"],"prefix":"10.1093","volume":"160","author":[{"given":"DANIEL J.","family":"O'HEARN","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Critical Care, and Division of Surgical Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland; and Department of Dermatology, Mayo Clinic and Foundation, Rochester, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KRISTIN M.","family":"LEIFERMAN","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, and Division of Surgical Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland; and Department of Dermatology, Mayo Clinic and Foundation, Rochester, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FREDERICK","family":"ASKIN","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, and Division of Surgical Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland; and Department of Dermatology, Mayo Clinic and Foundation, Rochester, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"STEVE N.","family":"GEORAS","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care, and Division of Surgical Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland; and Department of Dermatology, Mayo Clinic and Foundation, Rochester, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[1999,10,1]]},"reference":[{"key":"2026032708491636100_B1","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1126\/science.3131876","article-title":"Interleukin-2: inception, impact, and implications.","volume":"240","author":"Smith","year":"1988","journal-title":"Science"},{"key":"2026032708491636100_B2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.","volume":"271","author":"Rosenberg","year":"1994","journal-title":"J.A.M.A."},{"key":"2026032708491636100_B3","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"2026032708491636100_B4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/scd.1.1992.1.75","article-title":"Interferon-gamma potentiates the anti-tumor effect of cyclosporine- induced autoimmunity.","volume":"1","author":"Noga","year":"1992","journal-title":"J. Hematother."},{"key":"2026032708491636100_B5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1200\/JCO.1994.12.2.249","article-title":"Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer.","volume":"12","author":"Kennedy","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"2026032708491636100_B6","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0305-7372(94)90012-4","article-title":"Induced autologous graft-versus-host disease for the treatment of cancer.","volume":"20","author":"Kennedy","year":"1994","journal-title":"Cancer Treat. Rev."},{"key":"2026032708491636100_B7","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1002\/1097-0142(19861215)58:12<2764::AID-CNCR2820581235>3.0.CO;2-Z","article-title":"Clinical effects and toxicity of interleukin-2 in patients with cancer.","volume":"58","author":"Lotze","year":"1986","journal-title":"Cancer"},{"key":"2026032708491636100_B8","first-page":"368","article-title":"Radiologic characteristics of the thorax during therapy with interleukin-2.","volume":"84","author":"Morassut","year":"1992","journal-title":"Radiol. Med. (Torino)"},{"key":"2026032708491636100_B9","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4049\/jimmunol.137.5.1735","article-title":"Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.","volume":"137","author":"Rosenstein","year":"1986","journal-title":"J. Immunol."},{"key":"2026032708491636100_B10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0140-6736(82)91152-7","article-title":"Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma.","volume":"2","author":"Filley","year":"1982","journal-title":"Lancet"},{"key":"2026032708491636100_B11","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.1997.15.5.1870","article-title":"High dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.","volume":"15","author":"Breast Cancer Working Committee of the Autologous Blood and Marrow Transplant Registry of North America","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"2026032708491636100_B12","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/00007890-198912000-00001","article-title":"Immune mechanisms in cyclosporine-induced syngeneic graft-versus-host disease.","volume":"48","author":"Hess","year":"1989","journal-title":"Transplantaion"},{"key":"2026032708491636100_B13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4049\/jimmunol.125.1.238","article-title":"In vitro growth of murine T Cells: V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.","volume":"125","author":"Yron","year":"1980","journal-title":"J. Immunol."},{"key":"2026032708491636100_B14","first-page":"4420","article-title":"Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.","volume":"41","author":"Lotze","year":"1981","journal-title":"Cancer Res."},{"key":"2026032708491636100_B15","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1084\/jem.155.6.1823","article-title":"Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.","volume":"155","author":"Grimm","year":"1982","journal-title":"J. Exp. Med."},{"key":"2026032708491636100_B16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4049\/jimmunol.138.3.989","article-title":"Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.","volume":"138","author":"Mesler Muul, L., P. J. Spiess, E. P. Director, and S. A. Rosenberg","year":"1987","journal-title":"J. Immunol."},{"key":"2026032708491636100_B17","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1084\/jem.168.4.1419","article-title":"Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas.","volume":"168","author":"Itoh","year":"1988","journal-title":"J. Exp. Med."},{"key":"2026032708491636100_B18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.2910540103","article-title":"In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2: role of interleukin 5.","volume":"54","author":"Rivoltini","year":"1993","journal-title":"Int. J. Cancer"},{"key":"2026032708491636100_B19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.2910350217","article-title":"Induction of HLA class-II antigen expression on human carcinoma cell lines by IFN-gamma.","volume":"35","author":"Schwartz","year":"1985","journal-title":"Int. J. Cancer"},{"key":"2026032708491636100_B20","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1056\/NEJM199004053221404","article-title":"An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy.","volume":"322","author":"Klempner","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"2026032708491636100_B21","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.4049\/jimmunol.135.4.2865","article-title":"In vivo administration of purified human interleukin 2.","volume":"135","author":"Lotze","year":"1985","journal-title":"J. Immunol."},{"key":"2026032708491636100_B22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1989.7.1.7","article-title":"Cardiorespiratory effects of immunotherapy with interleukin-2.","volume":"7","author":"Lee","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"2026032708491636100_B23","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1378\/chest.94.4.750","article-title":"Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock.","volume":"94","author":"Ognibene","year":"1988","journal-title":"Chest"},{"key":"2026032708491636100_B24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1165\/ajrcmb\/7.1.58","article-title":"Interleukin-2 directly increases albumin permeability of bovine and human vascular endothelium in vitro.","volume":"7","author":"Downie","year":"1992","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2026032708491636100_B25","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4049\/jimmunol.145.3.873","article-title":"Role of IL-5 in IL-2-induced eosinophilia.","volume":"145","author":"Yamaguchi","year":"1990","journal-title":"J. Immunol."},{"key":"2026032708491636100_B26","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1365-2141.1990.tb07867.x","article-title":"Interleukin-2 treatment-associated eosinophilia is mediated by interleukin-5 production.","volume":"76","author":"Macdonald","year":"1990","journal-title":"Br. J. Haematol."},{"key":"2026032708491636100_B27","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1084\/jem.163.5.1085","article-title":"Murine eosinophil differentiation factor: an eosinophil-specific colony-stimulating factor with activity for human cells.","volume":"163","author":"Lopez","year":"1986","journal-title":"J. Exp. Med."},{"key":"2026032708491636100_B28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1084\/jem.167.1.219","article-title":"Recombinant human interleukin 5 is a selective activator of human eosinophil function.","volume":"167","author":"Lopez","year":"1988","journal-title":"J. Exp. Med."},{"key":"2026032708491636100_B29","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood.V78.6.1538.1538","article-title":"Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer.","volume":"78","author":"van Haelst Pisani, C., J. S. Kovach, H. Kata, K. M. Leiferman, G. J. Gleich, J. E. Silver, R. Dennin, and J. S. Abrams","year":"1991","journal-title":"Blood"},{"key":"2026032708491636100_B30","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.4049\/jimmunol.123.6.2925","article-title":"Cytotoxic properties of the eosinophil major basic protein.","volume":"123","author":"Gleich","year":"1979","journal-title":"J. Immunol."},{"key":"2026032708491636100_B31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0091-6749(85)90781-X","article-title":"Eosinophil and eosinophil granule-mediated pneumocyte injury.","volume":"76","author":"Ayars","year":"1985","journal-title":"J. Allergy Clin. Immunol."},{"key":"2026032708491636100_B32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1056\/NEJM198508013130502","article-title":"Dermal deposition of eosinophil granule major basic protein in atopic dermatitis.","volume":"313","author":"Leiferman","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"2026032708491636100_B33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00000421-199604000-00012","article-title":"Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma.","volume":"19","author":"Mani","year":"1996","journal-title":"Am. J. Clin. Oncol."},{"key":"2026032708491636100_B34","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.4049\/jimmunol.148.5.1471","article-title":"IFN-gamma induces expression of Fc Gamma RIII (CD16) on human eosinophils.","volume":"148","author":"Hartnell","year":"1992","journal-title":"J. Immunol."},{"key":"2026032708491636100_B35","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.4049\/jimmunol.156.11.4422","article-title":"Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes.","volume":"156","author":"Meagher","year":"1996","journal-title":"J. Immunol."},{"key":"2026032708491636100_B36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0002-9343(86)90053-7","article-title":"Chronic eosinophilic pneumonia.","volume":"80","author":"Grantham","year":"1986","journal-title":"Am. J. Med."},{"key":"2026032708491636100_B37","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1136\/thx.35.8.570","article-title":"Chronic eosinophilic pneumonia.","volume":"35","author":"Fox","year":"1980","journal-title":"Thorax"},{"key":"2026032708491636100_B38","first-page":"1","article-title":"Peripheral opacities in chronic eosinophilic pneumonia: the photographic negative of pulmonary oedema.","volume":"128","author":"Gaensler","year":"1977","journal-title":"A.J.R."}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/160\/4\/1361\/67427834\/ajrccm_160_4_1361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/160\/4\/1361\/67427834\/ajrccm_160_4_1361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:51:20Z","timestamp":1774615880000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/160\/4\/1361\/8529540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10,1]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[1999,10,1]]},"published-print":{"date-parts":[[1999,10,1]]}},"URL":"https:\/\/doi.org\/10.1164\/ajrccm.160.4.9902048","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1999,10]]},"published":{"date-parts":[[1999,10,1]]}}}